Skip to main content
SpringerLink
Log in
Book cover

Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions pp 131–173Cite as

Dermatologic Adverse Events from Cancer Treatments

  • Chapter
  • First Online:

Abstract

The incidences of adverse events to cancer treatments have increased as new treatments are being developed. Dermatologic adverse events (dAEs) strongly impact patients’ quality of life (QoL). Severe dAEs can result in dose reduction or discontinuation, which may compromise clinical outcomes and even lead to life-threatening conditions. Prevention, early diagnosis, and proper management of dAEs are crucial for optimizing anticancer response and maintaining QoL. This chapter addresses dAEs induced by cytotoxic and targeted therapies, radiotherapy, stem cell transplantation, immunotherapies, and CAR-T cell therapy. Proposed underling mechanisms and recommended treatment approaches for these dAEs are presented.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   129.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   109.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

Abbreviations

ADL:

Activities of daily living

ADRs:

Adverse drug reactions

AGA:

Androgenetic alopecia

AK:

Actinic keratoses

CAR-T Cell:

Chimeric antigen receptor-modified T lymphocytes

CIA:

Chemotherapy-induced alopecia

CombiDT:

Combination of dabrafenib with trametinib

CRS:

Cytokine release syndrome

CTLA-4:

Cytotoxic T lymphocyte antigen-4

DRESS:

Drug reaction with eosinophilia and systemic symptoms

EGFR:

Epidermal growth factor receptor

FAERS:

Food and Drug Administration Adverse Event Reporting System

FEC:

Fluorouracil/epirubicin/cyclophosphamide

GI:

gastrointestinal

GVHD:

Graft versus host disease

HFSR:

Hand-foot skin reaction

HSCT:

Hematopoietic stem cell transplantation

ICIs:

Immune checkpoint inhibitors

IHSR:

Immediate hypersensitivity reactions

irAEs:

Immune-related adverse events

irBP:

Immune-related bullous pemphigoid

JAKIs:

Janus kinase inhibitors

KAs:

Keratoacanthomas

MKIs:

Multi-targeted kinase inhibitors

MMF:

Mycophenolate mofetil

MPR:

Maculopapular rash

MSSA:

Methicillin-sensitive Staphylococcus aureus

nbUVB:

Narrow band ultraviolet B

NSCLC:

Non-small cell lung cancer

NV:

Nasal vestibulitis

pCIA:

persistent CIA

PLD:

Pegylated liposomal doxorubicin

PPE:

Papulopustular eruption

QoL:

Quality of life

RD:

Radiation dermatitis

SCARs:

Severe cutaneous adverse reactions

SCCs:

Squamous cell carcinomas

SCIs:

Systemic calcineurin inhibitors

SJS/TEN:

Stevens-Johnson syndrome/toxic epidermal necrolysis

SK:

Seborrheic keratoses

TCIs:

Topical calcineurin inhibitors

TCR:

T cell receptor

WHO:

World Health Organization

References

  • Aasi S, Silkiss R, Tang JY et al (2013) New onset of keratoacanthomas after vismodegib treatment for locally advanced basal cell carcinomas: a report of 2 cases. JAMA Dermatol 149(2):242–243

    Article  PubMed  PubMed Central  Google Scholar 

  • Abess A, Keel DM, Graham BS (2003) Flagellate hyperpigmentation following intralesional bleomycin treatment of verruca plantaris. Arch Dermatol 139(3):337–339

    Article  PubMed  Google Scholar 

  • Aoyama T, Takano M, Miyamoto M et al (2017) Is there any predictor for hypersensitivity reactions in gynecologic cancer patients treated with paclitaxel-based therapy? Cancer Chemother Pharmacol 80:65

    Article  CAS  PubMed  Google Scholar 

  • Asz-Sigall D, Gonzalez-de-Cossio-Hernandez AC, Rodriguez-Lobato E, Ortega-Springall MF, Vega-Memije ME, Arenas Guzman R (2016) Differential diagnosis of female-pattern hair loss. Skin Appendage Disord 2(1–2):18–21

    Article  PubMed  PubMed Central  Google Scholar 

  • Balagula Y, Barth Huston K, Busam KJ, Lacouture ME, Chapman PB, Myskowski PL (2011a) Dermatologic side effects associated with the MEK 1/2 inhibitor selumetinib (AZD6244, ARRY-142886). Investig New Drugs 29(5):1114–1121

    Article  CAS  Google Scholar 

  • Balagula Y, Rosen ST, Lacouture ME (2011b) The emergence of supportive oncodermatology: the study of dermatologic adverse events to cancer therapies. J Am Acad Dermatol 65(3):624–635

    Article  PubMed  Google Scholar 

  • Balagula Y, Wu S, Su X, Feldman DR, Lacouture ME (2012) The risk of hand foot skin reaction to pazopanib, a novel multikinase inhibitor: a systematic review of literature and meta-analysis. Investig New Drugs 30(4):1773–1781

    Article  CAS  Google Scholar 

  • Bastuji-Garin S, Fouchard N, Bertocchi M, Roujeau JC, Revuz J, Wolkenstein P (2000) SCORTEN: a severity-of-illness score for toxic epidermal necrolysis. J Invest Dermatol 115(2):149–153

    Article  CAS  PubMed  Google Scholar 

  • Belum VR, Benhuri B, Postow MA et al (2016) Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer 60:12–25

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Belum VR, Cercek A, Sanz-Motilva V, Lacouture ME (2013c) Dermatologic adverse events to targeted therapies in lower GI cancers: clinical presentation and management. Curr Treat Options in Oncol 14(3):389–404

    Article  Google Scholar 

  • Belum VR, Fischer A, Choi JN, Lacouture ME (2013b) Dermatological adverse events from BRAF inhibitors: a growing problem. Curr Oncol Rep 15(3):249–259

    Article  CAS  PubMed  Google Scholar 

  • Belum VR, Fontanilla Patel H, Lacouture ME, Rodeck U (2013a) Skin toxicity of targeted cancer agents: mechanisms and intervention. Future Oncol 9(8):1161–1170

    Article  CAS  PubMed  Google Scholar 

  • Belum VR, Marchetti MA, Dusza SW, Cercek A, Kemeny NE, Lacouture ME (2017) A prospective, randomized, double-blinded, split-face/chest study of prophylactic topical dapsone 5% gel versus moisturizer for the prevention of cetuximab-induced acneiform rash. J Am Acad Dermatol 77(3):577–579

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Belum VR, Marulanda K, Ensslin C et al (2015b) Alopecia in patients treated with molecularly targeted anticancer therapies. Ann Oncol 26(12):2496–2502

    CAS  PubMed  PubMed Central  Google Scholar 

  • Belum VR, Washington C, Pratilas CA, Sibaud V, Boralevi F, Lacouture ME (2015a) Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: a pooled analysis. Pediatr Blood Cancer 62(5):798–806

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Belum VR, Wu S, Lacouture ME (2013d) Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Investig New Drugs 31(4):1078–1086

    Article  CAS  Google Scholar 

  • Betticher DC, Delmore G, Breitenstein U et al (2013) Efficacy and tolerability of two scalp cooling systems for the prevention of alopecia associated with docetaxel treatment. Support Care Cancer 21(9):2565–2573

    Article  PubMed  Google Scholar 

  • Bolognia JL, Cooper DL, Glusac EJ (2008) Toxic erythema of chemotherapy: a useful clinical term. J Am Acad Dermatol 59(3):524–529

    Article  PubMed  Google Scholar 

  • Brown J, Burck K, Black D, Collins C (1991) Treatment of cytarabine acral erythema with corticosteroids. J Am Acad Dermatol 24(6 Pt 1):1023–1025

    Article  CAS  PubMed  Google Scholar 

  • Burris HA 3rd, Hurtig J (2010) Radiation recall with anticancer agents. Oncologist 15(11):1227–1237

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Capriotti K, Capriotti JA, Lessin S et al (2015) The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis. Br J Dermatol 173(3):842–845

    Article  CAS  PubMed  Google Scholar 

  • Capuano M, Sommese L, Pignalosa O et al (2015) Current clinical applications of extracorporeal photochemotherapy. Ther Apher Dial 19(2):103–110

    Article  CAS  PubMed  Google Scholar 

  • Carlos G, Anforth R, Clements A et al (2015) Cutaneous toxic effects of BRAF inhibitors alone and in combination with MEK inhibitors for metastatic melanoma. JAMA Dermatol 151(10):1103–1109

    Article  PubMed  Google Scholar 

  • Chandrakumar SF, Yeung J (2014) Cutaneous adverse events during vemurafenib therapy. J Cutan Med Surg 18(4):223–228

    Article  CAS  PubMed  Google Scholar 

  • Chen M, Chen J, Peng X et al (2017) The contribution of keratinocytes in capecitabine-stimulated hand-foot-syndrome. Environ Toxicol Pharmacol 49:81–88

    Article  CAS  PubMed  Google Scholar 

  • Chew L, Chuen VS (2009) Cutaneous reaction associated with weekly docetaxel administration. J Oncol Pharm Pract 15(1):29–34

    Article  CAS  PubMed  Google Scholar 

  • Chittari K, Tagboto S, Tan BB (2009) Cyclophosphamide-induced nail discoloration and skin hyperpigmentation: a rare presentation. Clin Exp Dermatol 34(3):405–406

    Article  CAS  PubMed  Google Scholar 

  • Choi JN (2014) Dermatologic adverse events to chemotherapeutic agents, part 2: BRAF inhibitors, MEK inhibitors, and ipilimumab. Semin Cutan Med Surg 33(1):40–48

    Article  PubMed  Google Scholar 

  • Clabbers JMK, Boers-Doets CB, Gelderblom H et al (2016) Xerosis and pruritus as major EGFRI-associated adverse events. Support Care Cancer 24(2):513–521

    Article  PubMed  Google Scholar 

  • Cook M, Johnson N, Zegzula HD, Schray M, Glissmeyer M, Sorenson L (2016) Prophylactic use of pentoxifylline (Trental) and vitamin E to prevent capsular contracture after implant reconstruction in patients requiring adjuvant radiation. Am J Surg 211(5):854–859

    Article  PubMed  Google Scholar 

  • Curry JL, Tetzlaff MT, Nagarajan P et al (2017) Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol 44(2):158–176

    Article  PubMed  Google Scholar 

  • Damsky W, King BA (2017) JAK inhibitors in dermatology: the promise of a new drug class. J Am Acad Dermatol 76(4):736–744

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Dreno B, Ribas A, Larkin J et al (2017) Incidence, course, and management of toxicities associated with cobimetinib in combination with vemurafenib in the coBRIM study. Ann Oncol 28(5):1137–1144

    Article  CAS  PubMed  Google Scholar 

  • Drilon A, Eaton AA, Schindler K et al (2016) Beyond the dose-limiting toxicity period: dermatologic adverse events of patients on phase 1 trials of the cancer therapeutics evaluation program. Cancer 122(8):1228–1237

    Article  CAS  PubMed  Google Scholar 

  • Elyasi S, Shojaee FSR, Allahyari A, Karimi G (2017) Topical Silymarin Administration for Prevention of Capecitabine-induced hand-foot syndrome: a randomized, double-blinded, placebo-controlled clinical trial. Phytother Res 31:1323

    Article  CAS  PubMed  Google Scholar 

  • Ensslin CJ, Rosen AC, Wu S, Lacouture ME (2013) Pruritus in patients treated with targeted cancer therapies: systematic review and meta-analysis. J Am Acad Dermatol 69(5):708–720

    Article  PubMed  PubMed Central  Google Scholar 

  • European Medicines Agency (2016) European Public Assessment Report: Erivdege. http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/002602/WC500146821.pdf

  • Fischer A, Wu S, Ho AL, Lacouture ME (2013) The risk of hand-foot skin reaction to axitinib, a novel VEGF inhibitor: a systematic review of literature and meta-analysis. Investig New Drugs 31(3):787–797

    Article  CAS  Google Scholar 

  • Fonia A, Cota C, Setterfield JF, Goldberg LJ, Fenton DA, Stefanato CM (2017) Permanent alopecia in patients with breast cancer after taxane chemotherapy and adjuvant hormonal therapy: Clinicopathologic findings in a cohort of 10 patients. J Am Acad Dermatol 76:948

    Article  CAS  PubMed  Google Scholar 

  • Freeman-Keller M, Kim Y, Cronin H, Richards A, Gibney G, Weber JS (2016) Nivolumab in resected and unresectable metastatic melanoma: characteristics of immune-related adverse events and association with outcomes. Clin Cancer Res 22(4):886–894

    Article  CAS  PubMed  Google Scholar 

  • Gandhi M, Brieva JC, Lacouture ME (2014) Dermatologic infections in cancer patients. Cancer Treat Res 161:299–317

    Article  PubMed  Google Scholar 

  • Gelmon K (1994) The taxoids: paclitaxel and docetaxel. Lancet 344(8932):1267–1272

    Article  CAS  PubMed  Google Scholar 

  • Giavina-Bianchi P, Patil SU, Banerji A (2017) Immediate hypersensitivity reaction to chemotherapeutic agents. J Allergy Clin Immunol Pract 5(3):593–599

    Article  PubMed  Google Scholar 

  • Gilbar P, Hain A, Peereboom VM (2009) Nail toxicity induced by cancer chemotherapy. J Oncol Pharm Pract 15(3):143–155

    Article  CAS  PubMed  Google Scholar 

  • Glaser DA, Hossain P, Perkins W et al (2015) Long-term safety and efficacy of bimatoprost solution 0.03% application to the eyelid margin for the treatment of idiopathic and chemotherapy-induced eyelash hypotrichosis: a randomized controlled trial. Br J Dermatol 172(5):1384–1394

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Goldinger SM, Stieger P, Meier B et al (2016) Cytotoxic cutaneous adverse drug reactions during anti-PD-1 therapy. Clin Cancer Res 22(16):4023–4029

    Article  CAS  PubMed  Google Scholar 

  • Gomez P, Lacouture ME (2011) Clinical presentation and management of hand-foot skin reaction associated with sorafenib in combination with cytotoxic chemotherapy: experience in breast cancer. Oncologist 16(11):1508–1519

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hackbarth M, Haas N, Fotopoulou C, Lichtenegger W, Sehouli J (2008) Chemotherapy-induced dermatological toxicity: frequencies and impact on quality of life in women’s cancers. Results of a prospective study. Support Care Cancer 16(3):267–273

    Article  PubMed  Google Scholar 

  • Hofheinz RD, Deplanque G, Komatsu Y et al (2016) Recommendations for the prophylactic Management of Skin Reactions Induced by epidermal growth factor receptor inhibitors in patients with solid tumors. Oncologist 21(12):1483–1491

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Hsiao YW, Lin YC, Hui RC, Yang CH (2011) Fulminant acneiform eruptions after administration of dovitinib in a patient with renal cell carcinoma. J Clin Oncol 29(12):e340–e341

    Article  PubMed  Google Scholar 

  • Huang V, Anadkat M (2011) Dermatologic manifestations of cytotoxic therapy. Dermatol Ther 24(4):401–410

    Article  PubMed  Google Scholar 

  • Hymes SR, Alousi AM, Cowen EW (2012a) Graft-versus-host disease: part I Pathogenesis and clinical manifestations of graft-versus-host disease. J Am Acad Dermatol 66(4):515 e1–18; quiz 33–4

    Article  PubMed  PubMed Central  Google Scholar 

  • Hymes SR, Alousi AM, Cowen EW (2012b) Graft-versus-host disease: part II Management of cutaneous graft-versus-host disease. J Am Acad Dermatol 66(4):535.e1–535.16 quiz 51–2

    Article  Google Scholar 

  • Ito J, Fujimoto D, Nakamura A et al (2017) Aprepitant for refractory nivolumab-induced pruritus. Lung Cancer 109:58–61

    Article  PubMed  Google Scholar 

  • Jain V, Bhandary S, Prasad GN, Shenoi SD (2005) Serpentine supravenous streaks induced by 5-fluorouracil. J Am Acad Dermatol 53(3):529–530

    Article  PubMed  Google Scholar 

  • Johnson DB, Wallender EK, Cohen DN et al (2013) Severe cutaneous and neurologic toxicity in melanoma patients during vemurafenib administration following anti-PD-1 therapy. Cancer Immunol Res 1(6):373–377

    Article  PubMed  PubMed Central  Google Scholar 

  • Jour G, Glitza IC, Ellis RM et al (2016) Autoimmune dermatologic toxicities from immune checkpoint blockade with anti-PD-1 antibody therapy: a report on bullous skin eruptions. J Cutan Pathol 43(8):688–696

    Article  PubMed  Google Scholar 

  • Julia Dai VRB, Shenhong W, Sibaud V, Lacouture ME (2017) Pigmentary changes in patients treated with targeted anticancer agents: a systematic review and meta-analysis. J Am Acad Dermatol 77(5):902–910.e2. https://doi.org/10.1016/j.jaad.2017.06.044

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Keating GM (2016) Cobimetinib plus Vemurafenib: a review in BRAF (V600) mutation-positive unresectable or metastatic melanoma. Drugs 76(5):605–615

    Article  CAS  PubMed  Google Scholar 

  • Kluger N, Jacot W, Frouin E et al (2012) Permanent scalp alopecia related to breast cancer chemotherapy by sequential fluorouracil/epirubicin/cyclophosphamide (FEC) and docetaxel: a prospective study of 20 patients. Ann Oncol 23(11):2879–2884

    Article  CAS  PubMed  Google Scholar 

  • Komen MM, Smorenburg CH, van den Hurk CJ, Nortier JW (2013) Factors influencing the effectiveness of scalp cooling in the prevention of chemotherapy-induced alopecia. Oncologist 18(7):885–891

    Article  PubMed  PubMed Central  Google Scholar 

  • Korman AM, Tyler KH, Kaffenberger BH (2017) Radiation recall dermatitis associated with nivolumab for metastatic malignant melanoma. Int J Dermatol 56(4):e75–ee7

    Article  PubMed  Google Scholar 

  • Kwong B, Danial C, Liu A, Chun KA, Chang AL (2017) Reversible cutaneous side effects of vismodegib treatment. Cutis 99(3):E19–e20

    PubMed  Google Scholar 

  • Kyllo RL, Anadkat MJ (2014a) Dermatologic adverse events to chemotherapeutic agents, part 1: cytotoxics, epidermal growth factor receptors, multikinase inhibitors, and proteasome inhibitors. Semin Cutan Med Surg 33(1):28–39

    Article  PubMed  Google Scholar 

  • Kyllo R, Anadkat M (2014b) Dermatologic adverse events to chemotherapeutic agents, part 1: cytotoxic agents, epidermal growth factor inhibitors, multikinase inhibitors, and proteasome inhibitors. Semin Cutan Med Surg 33(1):28–39

    Article  PubMed  Google Scholar 

  • Lacouture ME (2014) Dermatologic principles and practice in oncology: conditions of the skin, hair, and nails in cancer patients. John Wiley & Sons, Hoboken, NJ

    Google Scholar 

  • Lacouture ME (2015) Management of dermatologic toxicities. J Natl Compr Canc Netw 13(5 Suppl):686–689

    Article  CAS  PubMed  Google Scholar 

  • Lacouture ME, Anadkat MJ, Bensadoun RJ et al (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19(8):1079–1095

    Article  PubMed  PubMed Central  Google Scholar 

  • Lacouture ME, Ciccolini K, Kloos RT, Agulnik M (2014) Overview and management of dermatologic events associated with targeted therapies for medullary thyroid cancer. Thyroid 24(9):1329–1340

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lacouture ME, Dreno B, Ascierto PA et al (2016) Characterization and management of hedgehog pathway inhibitor-related adverse events in patients with advanced basal cell carcinoma. Oncologist 21(10):1218–1229

    Article  PubMed  PubMed Central  Google Scholar 

  • Lacouture ME, Duvic M, Hauschild A et al (2013b) Analysis of dermatologic events in vemurafenib-treated patients with melanoma. Oncologist 18(3):314–322

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lacouture ME, Maitland ML, Segaert S et al (2010a) A proposed EGFR inhibitor dermatologic adverse event-specific grading scale from the MASCC skin toxicity study group. Support Care Cancer 18(4):509–522

    Article  PubMed  Google Scholar 

  • Lacouture ME, Mitchell EP, Piperdi B et al (2010b) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-Emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28(8):1351–1357

    Article  CAS  PubMed  Google Scholar 

  • Lacouture ME, Reilly LM, Gerami P, Guitart J (2008a) Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib. Ann Oncol 19(11):1955–1961

    Article  CAS  PubMed  Google Scholar 

  • Lacouture ME, Schadendorf D, Chu CY et al (2013a) Dermatologic adverse events associated with afatinib: an oral ErbB family blocker. Expert Rev Anticancer Ther 13(6):721–728

    Article  CAS  PubMed  Google Scholar 

  • Lacouture ME, Wu S, Robert C et al (2008b) Evolving strategies for the management of hand-foot skin reaction associated with the multitargeted kinase inhibitors sorafenib and sunitinib. Oncologist 13(9):1001–1011

    Article  CAS  PubMed  Google Scholar 

  • Langer SW (2010) Extravasation of chemotherapy. Curr Oncol Rep 12(4):242–246

    Article  CAS  PubMed  Google Scholar 

  • Larsabal M, Marti A, Jacquemin C et al (2017) Vitiligo-like lesions occurring in patients receiving anti-programmed cell death-1 therapies are clinically and biologically distinct from vitiligo. J Am Acad Dermatol 76:863

    Article  PubMed  Google Scholar 

  • Lindner J, Hillmann K, Blume-Peytavi U et al (2012) Hair shaft abnormalities after chemotherapy and tamoxifen therapy in patients with breast cancer evaluated by optical coherence tomography. Br J Dermatol 167(6):1272–1278

    Article  CAS  PubMed  Google Scholar 

  • Liu HB, Wu Y, Lv TF et al (2013) Skin rash could predict the response to EGFR tyrosine kinase inhibitor and the prognosis for patients with non-small cell lung cancer: a systematic review and meta-analysis. PLoS One 8(1):e55128

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Long GV, Stroyakovskiy D, Gogas H et al (2014) Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med 371(20):1877–1888

    Article  CAS  PubMed  Google Scholar 

  • Lorusso D, Di Stefano A, Carone V, Fagotti A, Pisconti S, Scambia G (2007) Pegylated liposomal doxorubicin-related palmar-plantar erythrodysesthesia (‘hand-foot’ syndrome). Ann Oncol 18(7):1159–1164

    Article  CAS  PubMed  Google Scholar 

  • LoRusso PM, Rudin CM, Reddy JC et al (2011) Phase I trial of hedgehog pathway inhibitor vismodegib (GDC-0449) in patients with refractory, locally advanced or metastatic solid tumors. Clin Cancer Res 17(8):2502–2511

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Lou Y, Wang Q, Zheng J et al (2016) Possible pathways of Capecitabine-induced hand-foot syndrome. Chem Res Toxicol 29(10):1591–1601

    Article  CAS  PubMed  Google Scholar 

  • Macedo LT, Lima JP, dos Santos LV, Sasse AD (2014) Prevention strategies for chemotherapy-induced hand-foot syndrome: a systematic review and meta-analysis of prospective randomised trials. Support Care Cancer 22(6):1585–1593

    PubMed  Google Scholar 

  • Mangili G, Petrone M, Gentile C, De Marzi P, Vigano R, Rabaiotti E (2008) Prevention strategies in palmar-plantar erythrodysesthesia onset: the role of regional cooling. Gynecol Oncol 108(2):332–335

    Article  CAS  PubMed  Google Scholar 

  • McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E (2015) Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol 26(10):2017–2026

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Michot JM, Bigenwald C, Champiat S et al (2016) Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer 54:139–148

    Article  CAS  PubMed  Google Scholar 

  • Miteva M, Misciali C, Fanti PA, Vincenzi C, Romanelli P, Tosti A (2011) Permanent alopecia after systemic chemotherapy: a clinicopathological study of 10 cases. Am J Dermatopathol 33(4):345–350

    Article  PubMed  Google Scholar 

  • Naidoo J, Schindler K, Querfeld C et al (2016) Autoimmune bullous skin disorders with immune checkpoint inhibitors targeting PD-1 and PD-L1. Cancer Immunol Res 4(5):383–389

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Nangia J, Wang T, Osborne C et al (2017) Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial. JAMA 317(6):596–605

    Article  PubMed  Google Scholar 

  • Nayar N, Briscoe K, Fernandez Penas P (2016) Toxic epidermal necrolysis-like reaction with severe satellite cell necrosis associated with Nivolumab in a patient with Ipilimumab refractory metastatic melanoma. J Immunother 39(3):149–152

    Article  PubMed  Google Scholar 

  • Nikolaou V, Syrigos K, Saif MW (2016) Incidence and implications of chemotherapy related hand-foot syndrome. Expert Opin Drug Saf 15(12):1625–1633

    Article  CAS  PubMed  Google Scholar 

  • Palamaras I, Misciali C, Vincenzi C, Robles WS, Tosti A (2011) Permanent chemotherapy-induced alopecia: a review. J Am Acad Dermatol 64(3):604–606

    Article  PubMed  Google Scholar 

  • Park HJ, Lee JH, Kim SR et al (2016) A new practical desensitization protocol for Oxaliplatin-induced immediate hypersensitivity reactions: a necessary and useful approach. J Investig Allergol Clin Immunol 26(3):168–176

    Article  CAS  PubMed  Google Scholar 

  • Parker TL, Cooper DL, Seropian SE, Bolognia JL (2013) Toxic erythema of chemotherapy following i.v. BU plus fludarabine for allogeneic PBSC transplant. Bone Marrow Transplant 48(5):646–650

    Article  CAS  PubMed  Google Scholar 

  • Prevezas C, Matard B, Pinquier L, Reygagne P (2009) Irreversible and severe alopecia following docetaxel or paclitaxel cytotoxic therapy for breast cancer. Br J Dermatol 160(4):883–885

    Article  CAS  PubMed  Google Scholar 

  • Pugliese SB, Neal JW, Kwong BY (2015) Management of Dermatologic Complications of lung Cancer therapies. Curr Treat Options in Oncol 16(10):50

    Article  Google Scholar 

  • Riley P, Glenny AM, Worthington HV, Littlewood A, Clarkson JE, McCabe MG (2015) Interventions for preventing oral mucositis in patients with cancer receiving treatment: oral cryotherapy. Cochrane Database Syst Rev 12:CD011552

    Google Scholar 

  • Robert C, Schachter J, Long GV et al (2015) Pembrolizumab versus Ipilimumab in Advanced Melanoma. N Engl J Med 372(26):2521–2532

    Article  CAS  PubMed  Google Scholar 

  • Rosen AC, Balagula Y, Raisch DW et al (2014) Life-threatening dermatologic adverse events in oncology. Anti-Cancer Drugs 25(2):225–234

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Rugo HS, Melin SA, Voigt J (2017) Scalp cooling with adjuvant/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis. Breast Cancer Res Treat 163(2):199–205

    Article  PubMed  PubMed Central  Google Scholar 

  • Ruiz JN, Belum VR, Boers-Doets CB et al (2015) Nasal vestibulitis due to targeted therapies in cancer patients. Support Care Cancer 23(8):2391–2398

    Article  PubMed  PubMed Central  Google Scholar 

  • Saif MW, Katirtzoglou NA, Syrigos KN (2008) Capecitabine: an overview of the side effects and their management. Anti-Cancer Drugs 19(5):447–464

    CAS  PubMed  Google Scholar 

  • Sanborn RE, Sauer DA (2008) Cutaneous reactions to chemotherapy: commonly seen, less described, little understood. Dermatol Clin 26(1):103–119 ix

    Article  CAS  PubMed  Google Scholar 

  • Santoni M, Conti A, Andrikou K et al (2015) Risk of pruritus in cancer patients treated with biological therapies: a systematic review and meta-analysis of clinical trials. Crit Rev Oncol Hematol 96(2):206–219

    Article  PubMed  Google Scholar 

  • Scotte F, Banu E, Medioni J et al (2008) Matched case-control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel-induced onycholysis and cutaneous toxicity of the foot. Cancer 112(7):1625–1631

    Article  PubMed  Google Scholar 

  • Scotte F, Tourani JM, Banu E et al (2005) Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand. J Clin Oncol 23(19):4424–4429

    Article  PubMed  Google Scholar 

  • Sekulic A, Migden MR, Basset-Seguin N et al (2017) Long-term safety and efficacy of vismodegib in patients with advanced basal cell carcinoma: final update of the pivotal ERIVANCE BCC study. BMC Cancer 17(1):332

    Article  PubMed  PubMed Central  Google Scholar 

  • Sekulic A, Migden MR, Oro AE et al (2012) Efficacy and safety of vismodegib in advanced basal-cell carcinoma. N Engl J Med 366(23):2171–2179

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Shaitelman SF, Schlembach PJ, Arzu I et al (2015) Acute and short-term toxic effects of conventionally fractionated vs hypofractionated whole-breast irradiation: a randomized clinical trial. JAMA Oncol 1(7):931–941

    Article  PubMed  PubMed Central  Google Scholar 

  • Shreberk-Hassidim R, Ramot Y, Zlotogorski A (2017) Janus kinase inhibitors in dermatology: a systematic review. J Am Acad Dermatol 76(4):745–753 e19

    Article  CAS  PubMed  Google Scholar 

  • Sibaud V, Eid C, Belum VR et al (2017) Oral lichenoid reactions associated with anti-PD-1/PD-L1 therapies: clinicopathological findings. J Eur Acad Dermatol Venereol 31:e464

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Sibaud V, Leboeuf NR, Roche H et al (2016) Dermatological adverse events with taxane chemotherapy. Eur J Dermatol 26(5):427–443

    PubMed  PubMed Central  Google Scholar 

  • Sowerby L, Dewan AK, Granter S, Gandhi L, LeBoeuf NR (2017) Rituximab treatment of Nivolumab-induced bullous pemphigoid. JAMA Dermatol 153(6):603–605

    Article  PubMed  Google Scholar 

  • Spanemberg JC, Figueiredo MA, Cherubini K, Salum FG (2016) Low-level laser therapy: a review of its applications in the management of oral mucosal disorders. Altern Ther Health Med 22(6):24–31

    PubMed  Google Scholar 

  • Stander S, Siepmann D, Herrgott I, Sunderkotter C, Luger TA (2010) Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One 5(6):e10968

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Suvirya S, Agrawal A, Parihar A (2014) 5-Fluorouracil-induced bilateral persistent serpentine supravenous hyperpigmented eruption, bilateral mottling of palms and diffuse hyperpigmentation of soles. BMJ Case Rep 2014:bcr2014206793

    Article  PubMed  PubMed Central  Google Scholar 

  • Syrigou E, Dannos I, Kotteas E et al (2011) Hypersensitivity reactions to docetaxel: retrospective evaluation and development of a desensitization protocol. Int Arch Allergy Immunol 156(3):320–324

    Article  CAS  PubMed  Google Scholar 

  • Tallon B, Blanchard E, Goldberg LJ (2010) Permanent chemotherapy-induced alopecia: case report and review of the literature. J Am Acad Dermatol 63(2):333–336

    Article  PubMed  Google Scholar 

  • Tanaka R, Fujisawa Y, Sae I et al (2017) Severe hepatitis arising from ipilimumab administration, following melanoma treatment with nivolumab. Jpn J Clin Oncol 47(2):175–178

    Article  PubMed  Google Scholar 

  • Tang N, Ratner D (2016) Managing cutaneous side effects from targeted molecular inhibitors for melanoma and nonmelanoma skin cancer. Dermatol Surg 42(Suppl 1):S40–S48

    Article  CAS  PubMed  Google Scholar 

  • Teresi ME, Murry DJ, Cornelius AS (1993) Ifosfamide-induced hyperpigmentation. Cancer 71(9):2873–2875

    Article  CAS  PubMed  Google Scholar 

  • Tischer B, Huber R, Kraemer M, Lacouture ME (2017) Dermatologic events from EGFR inhibitors: the issue of the missing patient voice. Support Care Cancer 25(2):651–660

    Article  PubMed  Google Scholar 

  • Trueb RM (2007) Chemotherapy-induced anagen effluvium: diffuse or patterned? Dermatology (Basel, Switzerland) 215(1):1–2

    Article  Google Scholar 

  • Trueb RM (2010) Chemotherapy-induced hair loss. Skin Therapy Lett 15(7):5–7

    CAS  PubMed  Google Scholar 

  • US (2012) Food and Drug Administration Web site. Vismodegib. https://www.accessdata.fda.gov/drugsatfda_docs/label/2012/203388lbl.pdf. Accessed 26 June 2017

  • Valentine J, Belum VR, Duran J et al (2015) Incidence and risk of xerosis with targeted anticancer therapies. J Am Acad Dermatol 72(4):656–667

    Article  PubMed  Google Scholar 

  • van den Hurk CJ, Breed WP, Nortier JW (2012) Short post-infusion scalp cooling time in the prevention of docetaxel-induced alopecia. Support Care Cancer 20(12):3255–3260

    Article  PubMed  Google Scholar 

  • Villarreal CD, Alanis JC, Perez JC, Candiani JO (2016) Cutaneous graft-versus-host disease after hematopoietic stem cell transplant – a review. An Bras Dermatol 91(3):336–343

    Article  PubMed  PubMed Central  Google Scholar 

  • Vincenzi B, Tonini G, Santini D (2010) Aprepitant for erlotinib-induced pruritus. N Engl J Med 363(4):397–398

    Article  CAS  PubMed  Google Scholar 

  • von Moos R, Thuerlimann BJ, Aapro M et al (2008) Pegylated liposomal doxorubicin-associated hand-foot syndrome: recommendations of an international panel of experts. Eur J Cancer 44(6):781–790

    Article  CAS  Google Scholar 

  • Voskens CJ, Goldinger SM, Loquai C et al (2013) The price of tumor control: an analysis of rare side effects of anti-CTLA-4 therapy in metastatic melanoma from the ipilimumab network. PLoS One 8(1):e53745

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Vuerstaek JD, Frank J, Poblete-Gutierrez P (2007) Bleomycin-induced flagellate dermatitis. Int J Dermatol 46(Suppl 3):3–5

    Article  PubMed  Google Scholar 

  • Weber JS, Dummer R, de Pril V, Lebbe C, Hodi FS, Investigators MDX (2013) Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab: detailed safety analysis from a phase 3 trial in patients with advanced melanoma. Cancer 119(9):1675–1682

    Article  CAS  PubMed  Google Scholar 

  • Weber JS, Kahler KC, Hauschild A (2012) Management of immune-related adverse events and kinetics of response with ipilimumab. J Clin Oncol 30(21):2691–2697

    Article  CAS  PubMed  Google Scholar 

  • Weber JS, Yang JC, Atkins MB, Disis ML (2015) Toxicities of immunotherapy for the practitioner. J Clin Oncol 33(18):2092–2099

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  • Wolchok JD, Neyns B, Linette G et al (2010) Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol 11(2):155–164

    Article  CAS  PubMed  Google Scholar 

  • Wolff D, Ayuk F, Elmaagacli A et al (2013) Current practice in diagnosis and treatment of acute graft-versus-host disease: results from a survey among German-Austrian-Swiss hematopoietic stem cell transplant centers. Biol Blood Marrow Transplant 19(5):767–776

    Article  PubMed  Google Scholar 

  • Wong RK, Bensadoun RJ, Boers-Doets CB et al (2013) Clinical practice guidelines for the prevention and treatment of acute and late radiation reactions from the MASCC skin toxicity study group. Support Care Cancer 21(10):2933–2948

    Article  PubMed  Google Scholar 

  • Wu J, Lee YY, Su SC et al (2015) Stevens-Johnson syndrome and toxic epidermal necrolysis in patients with malignancies. Br J Dermatol 173(5):1224–1231

    Article  CAS  PubMed  Google Scholar 

  • Wyatt AJ, Leonard GD, Sachs DL (2006) Cutaneous reactions to chemotherapy and their management. Am J Clin Dermatol 7(1):45–63

    Article  PubMed  Google Scholar 

  • Yeh CN, Chung WH, Su SC et al (2014) Fas/Fas ligand mediates keratinocyte death in sunitinib-induced hand-foot skin reaction. J Invest Dermatol 134(11):2768–2775

    Article  CAS  PubMed  Google Scholar 

  • Zhang RX, Wu XJ, Wan DS et al (2012) Celecoxib can prevent capecitabine-related hand-foot syndrome in stage II and III colorectal cancer patients: result of a single-center, prospective randomized phase III trial. Ann Oncol 23(5):1348–1353

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgment

We would like to thank Ms. Bernadette Murphy for clinical photography.

Author information

Authors and Affiliations

  1. Dermatology Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA

    Jennifer Wu, Alina Markova & Mario E. Lacouture

  2. Department of Dermatology, Drug Hypersensitivity Clinical and Research Center, Chang Gung Memorial Hospital, Taipei, Taiwan

    Jennifer Wu

  3. College of Medicine, Chang Gung University, Taoyuan, Taiwan

    Jennifer Wu

Authors
  1. Jennifer Wu
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Alina Markova
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mario E. Lacouture
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Mario E. Lacouture .

Editor information

Editors and Affiliations

  1. University of Toronto Medical School, Sunnybrook Health Sciences Centre, Toronto, ON, Canada

    Neil H. Shear

  2. Department of Dermatology, Emek Medical Center, Afula, Israel

    Roni P. Dodiuk-Gad

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer Nature Singapore Pte Ltd.

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Wu, J., Markova, A., Lacouture, M.E. (2019). Dermatologic Adverse Events from Cancer Treatments. In: Shear, N., Dodiuk-Gad, R. (eds) Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions. Adis, Singapore. https://doi.org/10.1007/978-981-13-1489-6_10

Download citation

  • DOI: https://doi.org/10.1007/978-981-13-1489-6_10

  • Published:

  • Publisher Name: Adis, Singapore

  • Print ISBN: 978-981-13-1488-9

  • Online ISBN: 978-981-13-1489-6

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation